Cohort

20 High-Impact Companies Selected to Join Cohort 4 of Venture for ClimateTech to Curb Greenhouse Gas Emissions

Retrieved on: 
onsdag, maj 29, 2024
Recycling, CO2, BIPOC, DAC, Biopolymer, Direct air capture, Calcium carbonate, Synthetic biology, Glass, Built environment, Wind, Carbon, Atmosphere, Silicon, Female, Cohort, HERE, Biodiversity, For, Textile, Electricity, Renewable energy

The 20 companies were selected from a pool of 327 applicants across 45 different countries.

Key Points: 
  • The 20 companies were selected from a pool of 327 applicants across 45 different countries.
  • The 20 companies were then selected for Cohort 4 joining the ranks of emerging Venture for ClimateTech “companies to watch”.
  • Venture for ClimateTech has helped 39 companies, since the program’s inception.
  • To follow these companies’ progress, and the impacts made by others in the program, subscribe to the For ClimateTech monthly newsletter ( HERE ).

65 Startups Named to MedTech Innovator 2024 Cohort

Retrieved on: 
onsdag, maj 29, 2024
Biotechnology, Finance, Health, Start-Up, Medical Devices, Health Technology, Professional Services, Business, Partnership, Patient, American Heart, MTI, Cohort, Johnson & Johnson, FDA, Ecosystem, MTEC, SME, Accelerator, Heart, ASPS, Society, Medtech, Pharmaceutical industry

MedTech Innovator , the world's largest accelerator of medical technology companies, today announced its 2024 Accelerator Cohort .

Key Points: 
  • MedTech Innovator , the world's largest accelerator of medical technology companies, today announced its 2024 Accelerator Cohort .
  • Since launching MedTech Innovator, our more than 600 graduates have received 310 FDA approvals and clearances and secured $8 billion in follow-on funding,” said Paul Grand, CEO and founder of MedTech Innovator.
  • “Having evaluated thousands of applicants since November, I can tell you definitively that the 2024 MedTech Innovator Cohort represents the best emerging startups around the globe.
  • The MedTech Innovator 2024 Cohort includes:

Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial

Retrieved on: 
tisdag, maj 28, 2024
Patient, Pharmacokinetics, Cancer, SRC, Plasma, Cohort, Toxicity, Clinical trial, AACR, APRE, FDA, Therapy, ATR, Safety, Biomarker, DDR, Poster, Infrared spectroscopy correlation table, Part, Mutation, Day, Pharmaceutical industry

DOYLESTOWN, Pa., May 28, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that the Safety Review Committee (SRC) overseeing the ongoing ABOYA-119 clinical trial has determined that dosing of patients with ATRN-119 at 800 mg once daily (Cohort 6) can commence and that Cohort 6 is open for enrollment. This decision follows review of the safety and pharmacokinetic data from patients treated at 550 mg once daily (Cohort 5).

Key Points: 
  • This decision follows review of the safety and pharmacokinetic data from patients treated at 550 mg once daily (Cohort 5).
  • “Pharmacokinetic data show that the duration of systemic exposure substantially increases with each dose level of ATRN-119.
  • A total of 17 patients have been enrolled in the first five cohorts of the dose escalation stage (50 mg once daily, 100 mg once daily, 200 mg once daily, 350 mg once daily, and 550 mg once daily).
  • The data demonstrate near dose proportional exposure following oral administration of ATRN-119 doses between 50 mg once daily to 550 mg once daily.

Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting

Retrieved on: 
torsdag, maj 23, 2024
IOV, Interleukin, McCormick Place, ICI, Patient, TIL, Pembrolizumab, Cohort, Food, Clinical trial, CDT, FDA, EDT, Disease, Safety, SAN, RECIST, Cancer, Melanoma, ASCO, Webcast, Pharmaceutical industry

SAN CARLOS, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced updated clinical data for lifileucel in combination with pembrolizumab in frontline advanced melanoma, as well as translational data, for the upcoming 2024 ASCO Annual Meeting to be held May 31 – June 4, 2024, at McCormick Place in Chicago, IL and online.

Key Points: 
  • Unprecedented response rates, as well as deep and durable responses, were observed in patients with frontline advanced melanoma who were naïve to immune checkpoint inhibitor (ICI) therapy.
  • Confirmed ORR was 65.2%, including 7 (30.4%) complete responses and 8 (34.8%) partial responses by RECIST v1.1.
  • TILVANCE-301 is a global, randomized, registrational Phase 3 trial to support accelerated and full U.S. approvals of lifileucel in combination with pembrolizumab in frontline advanced melanoma.
  • The live and archived webcast can be accessed in the Investors section of the Company’s website, IR.Iovance.com for one year.

Asimily Selected for the U.S. Department of Energy’s Clean Energy Cybersecurity Accelerator

Retrieved on: 
onsdag, maj 22, 2024
Cohort, NREL, IoMT, ARIES, CECA, Internet of things, Research, Environment, Acceleration, OT, Risk management

SUNNYVALE, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Asimily , an industry-leading risk management platform for IoMT, OT and IoT devices, today announced it has been selected to participate in the second cohort of the U.S. Department of Energy’s (DOE’s) Clean Energy Cybersecurity Accelerator™ (CECA).

Key Points: 
  • SUNNYVALE, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Asimily , an industry-leading risk management platform for IoMT, OT and IoT devices, today announced it has been selected to participate in the second cohort of the U.S. Department of Energy’s (DOE’s) Clean Energy Cybersecurity Accelerator™ (CECA).
  • “Increasing cybersecurity threats to utilities make it essential that this critical infrastructure is well protected,” said Shankar Somasundaram, CEO and Founder, Asimily.
  • Selected participants benefit from access to the National Renewable Energy Laboratory’s (NREL’s) unique evaluation capabilities, where solutions will undergo rigorous testing.
  • Asimily, alongside the other Cohort 2 participants, will receive competitive experience and a professional third-party evaluation of its technology.

Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting

Retrieved on: 
tisdag, maj 21, 2024
Patient, InSight, PD, Cohort, Cancer prevention, Medication, Safety, Adenoma, Principal investigator, MD, Acquisition, Research institute, Duodenum, PR, Gastrointestinal disease, Pharmaceutical industry

The study was partially supported by $20M in grant funding from the Cancer Prevention and Research Institute of Texas under product development awards DP22053 and DP190069.

Key Points: 
  • The study was partially supported by $20M in grant funding from the Cancer Prevention and Research Institute of Texas under product development awards DP22053 and DP190069.
  • Polyp outcomes were classified into Progressive Disease (PD: >20% increase in polyp burden), Stable Disease (SD: ± 20% change in polyp burden) or Partial Response (PR: >20% reduction in polyp burden).
  • In the duodenum, 14/18 (78%) patients were non-progressors with 11/18 (61%) of these patients with PR.
  • Polyp burden data at 12 months compared with baseline will be presented at the InSIGHT scientific conference in Barcelona on June 19-22, 2024.

Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Retrieved on: 
onsdag, maj 15, 2024
Patient, Cohort, BID, Exercise, Therapy, Disease, Safety, Interstitial, Fibroblast, University of Giessen, Biomarker, Acquisition, Șaeș, Fibrosis, Research, IPF, Research and development, Administration, ALRN, Pharmaceutical industry

AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron” or the “Company”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.

Key Points: 
  • AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron” or the “Company”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.
  • The Phase 1b study is ongoing, with topline results from the high-dose cohort expected in the third quarter of 2024.
  • Net Loss: Net loss for the quarter ended March 31, 2024, was $7.1 million, compared to $4.8 million for the corresponding quarter in 2023.
  • The basic and diluted net loss per share for the quarter ended March 31, 2024 was $0.86 compared to $1.05 for the quarter ended March 31, 2023.

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results

Retrieved on: 
onsdag, maj 15, 2024
Molecular imaging, Mayo Clinic, Investment, PRRT, FDA, BMY, IND, EANM, Prostate, Ligand, Research, Antibody, PET, Bangladesh Technical Education Board, Stony Brook University, PSMA, Fortis Healthcare, Therapeutic index, Society, Neoplasm, Small business, CMC, Melanoma, Cohort, ATM, Bristol Myers Squibb, Business, CATX, Food, Disease, Safety, Cancer, Patient, Radiopharmaceutical, Adenocarcinoma, Nivolumab, Diagnosis, SNMMI, Therapy, Prostate cancer, LNTH, Nuclear medicine, Acquisition, NETS, Glomus tumor, MC1R, Pharmaceutical industry

SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced first quarter financial results for the period ended March 31, 2024.

Key Points: 
  • SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced first quarter financial results for the period ended March 31, 2024.
  • “I am proud of the progress we are making with our clinical-stage proprietary radiopharmaceuticals,” said Thijs Spoor, Perspective Therapeutics' CEO.
  • The Company was informed by the investigator that preliminary data readout is expected in the second half of 2024.
  • Updated results from Cohorts 1 and 2 of the Phase 1/2a study are expected in the second half of 2024.

Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

Retrieved on: 
onsdag, maj 15, 2024
Medicine, MPH, Patient, Retina, Doctor of Philosophy, Cohort, Consultant, Clinical trial, University, Stargardt disease, FDA, Safety, Life, Vaccine, College of Medicine, ARC, University of Arizona, Gardian, Pharmaceutical industry

"The completion of dosing for Cohort 2 participants signifies an important clinical milestone for our pioneering modifier gene therapy,” said Huma Qamar, MD, MPH, Chief Medical Officer of Ocugen.

Key Points: 
  • "The completion of dosing for Cohort 2 participants signifies an important clinical milestone for our pioneering modifier gene therapy,” said Huma Qamar, MD, MPH, Chief Medical Officer of Ocugen.
  • We look forward to sharing preliminary safety and efficacy data from Phase 1 of the clinical trial.”
    Six patients with Stargardt disease have been dosed in the Phase 1/2 clinical trial to date.
  • An additional three patients will be dosed with the high dose (Cohort 3) of OCU410ST in the dose-escalation phase.
  • The GARDian clinical trial will assess the safety and efficacy of unilateral subretinal administration of OCU410ST in subjects with Stargardt disease and will be conducted in two phases.

Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates

Retrieved on: 
fredag, maj 10, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Insurance, MECP2, Cell, Patient, Information technology, Cohort, Toxicity, Research and development, Inc., Investment, AAV, Clinical trial, Disease, Safety, DSM-IV codes, Conference, Gene, Rett syndrome, IRSF, Society, Aes, Administration, Food and Drug Administration, Annual general meeting, Pharmaceutical industry

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced first quarter 2024 financial results and highlighted recent corporate updates.

Key Points: 
  • Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced first quarter 2024 financial results and highlighted recent corporate updates.
  • “We were pleased to present data at the ASGCT Annual Meeting earlier this week, which continued to show that NGN-401 has been generally well-tolerated.
  • Cash outflows pertaining to the transaction with Neoleukin Therapeutics, including the offering costs associated with the pre-closing financing, were $9.6 million for the quarter ended March 31, 2024.
  • Net Loss: Net loss was $16.9 million for the three months ended March 31, 2024 compared to net loss of $12.3 million for the three months ended March 31, 2023.